Posted by Michael Wonder on 05 Aug 2023
Iveric Bio receives US FDA approval for Izervay (avacincaptad pegol intravitreal solution), a new treatment for geographic atrophy
5 August 2023 - Izervay is the only approved GA treatment with a statistically significant reduction in the rate of geographic atrophy progression at the 12 month primary endpoint across two Phase 3 clinical trials.
Astellas today announced the US FDA approved Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy secondary to age-related macular degeneration on 4 August 2023.
